![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Effect of Chronic Kidney Disease on the Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir in Subjects with HCV Genotype 1 Infection
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Diana Shuster1, Rajeev Menon1, Daniel E. Cohen2, Doerthe Eckert3, Amit Khatri1
1AbbVie Inc., Clinical Pharmacology and Pharmacometrics, North Chicago, IL, USA; 2AbbVie Inc., Infectious Disease Development, North Chicago, IL, USA; 3AbbVie Deutschland GmbH & Co.KG, Clinical Pharmacology and Pharmacometrics, Ludwigshafen, Germany
AASLD: RUBY-I: Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin in Non-Cirrhotic HCV Genotype 1-Infected Patients With Severe Renal Impairment or End-Stage Renal Disease - (12/16/15)
AASLD/2014: The Pharmacokinetics and Safety of the Direct Acting Antiviral Regimen of ABT-450/r, Ombitasvir with/without Dasabuvir in Subjects with Mild, Moderate and Severe Renal Impairment Compared to Subjects with Normal Renal Function.....http://www.natap.org/2014/AASLD/AASLD_55.htm
![AASLD1.gif](../images/122215/122215-2/AASLD1.gif)
![AASLD2.gif](../images/122215/122215-2/AASLD2.gif)
![AASLD3.gif](../images/122215/122215-2/AASLD3.gif)
![AASLD4.gif](../images/122215/122215-2/AASLD4.gif)
![AASLD5.gif](../images/122215/122215-2/AASLD5.gif)
![AASLD6.gif](../images/122215/122215-2/AASLD6.gif)
![AASLD7.gif](../images/122215/122215-2/AASLD7.gif)
![AASLD8.gif](../images/122215/122215-2/AASLD8.gif)
![AASLD9.gif](../images/122215/122215-2/AASLD9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|